The Patient Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
Activate Your Account with an access code or Create a New Account
Pamela L. Kunz
Medical oncologist, Gastrointestinal specialist
Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center
Bio:
Dr. Kunz specializes in the treatment of gastrointestinal malignancies with an expertise in the care of patients with neuroendocrine tumors (NETs). She has developed broad investigative programs in the field of neuroendocrine tumors, encompassing clinical trials, population sciences, and translational correlates. She is the Principal Investigator on numerous clinical trials. She is the Director of the Stanford Neuroendocrine Tumor Program. She currently serves on the National Comprehensive Cancer Network (NCCN) Neuroendocrine Tumors Guidelines Panel, the Neuroendocrine Tumor Taskforce of the National Cancer institute, the NANETS Guidelines and Executive Committees, and leads the NET Working Group of the Eastern Cooperative Oncology Group (ECOG).
- 875 Blake Wilbur Drive
- Palo Alto, CA 94304
- Phone: 650-498-6000
- 875 Blake Wilbur Drive
- Palo Alto, CA 94304
- Phone: 650-498-6000
Practice Areas
Professional Education
- Medical Education: Dartmouth Geisel School of Medicine (2001) NH
- Residency: Stanford University School of Medicine (2004) CA
- Residency: Stanford University School of Medicine (2005) CA
- Fellowship: Stanford University School of Medicine (2007) CA
- Board Certification: Medical Oncology, American Board of Internal Medicine (2010)
- Board Certification, Oncology, ABIM (2010)
Administrative Appointments
- Director, Stanford Neuroendocrine Tumor Program (2015 - Present)
- Leader, GI Oncology Clinical Research Program (2015 - Present)
- Director, Inpatient Oncology (Med 10) (2013 - Present)
Publications
-
Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma
Nagpal, S., Recht, C. K., Bertrand, S., Thomas, R. P., Ajlan, A., & Recht, L. D. (2015). Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma. JOURNAL OF NEURO-ONCOLOGY, 123(2), 277-282. -
Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors
Narayanan, S., & Kunz, P. L. (2015). Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(1), 109-117. -
Single-versus Multifraction Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma: Outcomes and Toxicity
Pollom, E. L., Alagappan, M., von Eyben, R., Kunz, P. L., Fisher, G. A., & Chang, D. T. (2014). Single-versus Multifraction Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma: Outcomes and Toxicity. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 90(4), 918-925. -
Postradiotherapy CA19-9 Kinetics Correlate With Outcomes in Patients With Pancreatic Adenocarcinoma
Shultz, D. B., Chan, C., Shaffer, J. L., Kunz, P. L., Koong, A. C., & Chang, D. T. (2014). Postradiotherapy CA19-9 Kinetics Correlate With Outcomes in Patients With Pancreatic Adenocarcinoma. PANCREAS, 43(5), 777-783.
-
Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness
Worhunsky, D. J., Krampitz, G. W., Poullos, P. D., Visser, B. C., Kunz, P. L., & Poultsides, G. A. (2014). Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness. HPB, 16(4), 304-311.
-
Reassessment of the Current American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Tumors
Qadan, M., Ma, Y., Visser, B. C., Kunz, P. L., Fisher, G. A., & Poultsides, G. A. (2014). Reassessment of the Current American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Tumors. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 218(2), 188-195.
-
False positive 18F-fluorodeoxyglucose positron emission tomography/computed tomography liver lesion mimicking metastasis in 2 patients with gastroesophageal cancer.
Paudel, N., Kunz, P. L., Poultsides, G. A., Koong, A. C., & Chang, D. T. (2014). False positive 18F-fluorodeoxyglucose positron emission tomography/computed tomography liver lesion mimicking metastasis in 2 patients with gastroesophageal cancer. Practical radiation oncology, 4(6), 368-371.
-
Seventh Edition (2010) of the AJCC/UICC Staging System for Gastric Adenocarcinoma: Is there Room for Improvement?
Patel, M. I., Rhoads, K. F., Ma, Y., Ford, J. M., Visser, B. C., & Poultsides, G. A. (2013). Seventh Edition (2010) of the AJCC/UICC Staging System for Gastric Adenocarcinoma: Is there Room for Improvement?. ANNALS OF SURGICAL ONCOLOGY, 20(5), 1631-1638.
-
Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors
Kunz, P. L., Reidy-Lagunes, D., Anthony, L. B., Bertino, E. M., Brendtro, K., & Yao, J. C. (2013). Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors. PANCREAS, 42(4), 557-577.
-
Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
Shah, M. A., Wainberg, Z. A., Catenacci, D. Vt., Hochster, H. S., Ford, J., & Bottaro, D. P. (2013). Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. PLOS ONE, 8(3).
-
Everolimus Causing Severe Hypertriglyceridemia and Acute Pancreatitis
Subramaniam, S., Zell, J. A., & Kunz, P. L. (2013). Everolimus Causing Severe Hypertriglyceridemia and Acute Pancreatitis. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(1), 5-9.
-
Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors
Kunz, P. L., He, A. R., Colevas, A. D., Pishvaian, M. J., Hwang, J. J., & Marshall, J. L. (2012). Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors. INVESTIGATIONAL NEW DRUGS, 30(6), 2364-2370.
-
Neoadjuvant Imatinib for Borderline Resectable GIST
Koontz, M. Z., Visser, B. M., & Kunz, P. L. (2012). Neoadjuvant Imatinib for Borderline Resectable GIST. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(12), 1477-1482.
-
Capecitabine-Induced Chest Pain Relieved by Diltiazem
Ambrosy, A. P., Kunz, P. L., Fisher, G. A., & Witteles, R. M. (2012). Capecitabine-Induced Chest Pain Relieved by Diltiazem. AMERICAN JOURNAL OF CARDIOLOGY, 110(11), 1623-1626.
-
Long-Term Survivors of Gastric Cancer: A California Population-Based Study
Kunz, P. L., Gubens, M., Fisher, G. A., Ford, J. M., Lichtensztajn, D. Y., & Clarke, C. A. (2012). Long-Term Survivors of Gastric Cancer: A California Population-Based Study. JOURNAL OF CLINICAL ONCOLOGY, 30(28), 3507-3515.
-
Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features
Chang, D. T., Pai, R. K., Rybicki, L. A., DiMaio, M. A., Limaye, M., & Pai, R. K. (2012). Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. MODERN PATHOLOGY, 25(8), 1128-1139.
-
Pancreatic Neuroendocrine Tumors: Radiographic Calcifications Correlate with Grade and Metastasis
Poultsides, G. A., Huang, L. C., Chen, Y., Visser, B. C., Pai, R. K., & Norton, J. A. (2012). Pancreatic Neuroendocrine Tumors: Radiographic Calcifications Correlate with Grade and Metastasis. ANNALS OF SURGICAL ONCOLOGY, 19(7), 2295-2303.
-
Neuroendocrine Tumors Clinical Practice Guidelines in Oncology
Kulke, M. H., Benson, A. B., Bergsland, E., Berlin, J. D., Blaszkowsky, L. S., & Dwyer, M. A. (2012). Neuroendocrine Tumors Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(6), 724-764.
-
Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma
Abelson, J. A., Murphy, J. D., Minn, A. Y., Chung, M., Fisher, G. A., & Chang, D. T. (2012). Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 82(4), E595-E601.
-
HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population: Clinicopathologic Analysis With Proposed Approach to HER2 Assessment
Kunz, P. L., Mojtahed, A., Fisher, G. A., Ford, J. M., Chang, D. T., & Pai, R. K. (2012). HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population: Clinicopathologic Analysis With Proposed Approach to HER2 Assessment. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 20(1), 13-24.
-
SINGLE-FRACTION STEREOTACTIC BODY RADIATION THERAPY AND SEQUENTIAL GEMCITABINE FOR THE TREATMENT OF LOCALLY ADVANCED PANCREATIC CANCER
Schellenberg, D., Kim, J., Ciristman-Skieller, C., Chun, C. L., Columbo, L. A., & Koong, A. C. (2011). SINGLE-FRACTION STEREOTACTIC BODY RADIATION THERAPY AND SEQUENTIAL GEMCITABINE FOR THE TREATMENT OF LOCALLY ADVANCED PANCREATIC CANCER. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(1), 181-188.
-
Intensity-Modulated Radiation Therapy Versus Conventional Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal
Bazan, J. G., Hara, W., Hsu, A., Kunz, P. A., Ford, J., & Chang, D. T. (2011). Intensity-Modulated Radiation Therapy Versus Conventional Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal. CANCER, 117(15), 3342-3351.
-
Pancreatic Endocrine Tumors With Major Vascular Abutment, Involvement, or Encasement and Indication for Resection
Norton, J. A., Harris, E. J., Chen, Y., Visser, B. C., Poultsides, G. A., & Jensen, R. T. (2011). Pancreatic Endocrine Tumors With Major Vascular Abutment, Involvement, or Encasement and Indication for Resection. ARCHIVES OF SURGERY, 146(6), 724-732.
-
F-18-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases
Zissen, M. H., Kunz, P., Subbarayan, M., Chin, F. T., Conti, P. S., & Quon, A. (2011). F-18-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases. NUCLEAR MEDICINE COMMUNICATIONS, 32(5), 343-347.
-
Expression of p16(INK4A) But Not Hypoxia Markers or Poly Adenosine Diphosphate-Ribose Polymerase Is Associated With Improved Survival in Patients With Pancreatic Adenocarcinoma
Chang, D. T., Chapman, C. H., Norton, J. A., Visser, B., Fisher, G. A., & Pai, R. K. (2010). Expression of p16(INK4A) But Not Hypoxia Markers or Poly Adenosine Diphosphate-Ribose Polymerase Is Associated With Improved Survival in Patients With Pancreatic Adenocarcinoma. CANCER, 116(22), 5179-5187.
-
Comparison of Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy as Adjuvant Therapy for Gastric Cancer
Minn, A. Y., Hsu, A., La, T., Kunz, P., Fisher, G. A., & Chang, D. T. (2010). Comparison of Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy as Adjuvant Therapy for Gastric Cancer. CANCER, 116(16), 3943-3952.
-
(18)FLUORODEOXYGLUCOSE PET IS PROGNOSTIC OF PROGRESSION-FREE AND OVERALL SURVIVAL IN LOCALLY ADVANCED PANCREAS CANCER TREATED WITH STEREOTACTIC RADIOTHERAPY
Schellenberg, D., Quon, A., Minn, A. Y., Graves, E. E., Kunz, P., & Chang, D. T. (2010). (18)FLUORODEOXYGLUCOSE PET IS PROGNOSTIC OF PROGRESSION-FREE AND OVERALL SURVIVAL IN LOCALLY ADVANCED PANCREAS CANCER TREATED WITH STEREOTACTIC RADIOTHERAPY. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 77(5), 1420-1425.
-
Pathological response after chemoradiation for T3 rectal cancer
Chennupati, S. K., Kamaya, A., Fisher, G. A., Ford, J. M., Kunz, P., & Chang, D. T. (2010). Pathological response after chemoradiation for T3 rectal cancer. COLORECTAL DISEASE, 12(7), E24-E30.
-
Pathological response after chemoradiation for T3 rectal cancer.
Chennupati, S. K., Kamaya, A., Fisher, G. A., Ford, J. M., Kunz, P., & Chang, D. T. (2010). Pathological response after chemoradiation for T3 rectal cancer. Colorectal disease , 12(7 Online), e24-30.
-
Advances in the treatment of gastroenteropancreatic neuroendocrine tumors.
Kunz, P. L., & Fisher, G. A. (2010). Advances in the treatment of gastroenteropancreatic neuroendocrine tumors. Clinical and experimental gastroenterology, 3, 79-86.
-
Multimodality treatment with intensity modulated radiation therapy for esophageal cancer
La, T. H., Minn, A. Y., Su, Z., Fisher, G. A., Ford, J. M., & Chang, D. T. (2010). Multimodality treatment with intensity modulated radiation therapy for esophageal cancer. DISEASES OF THE ESOPHAGUS, 23(4), 300-308.
-
Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis
Chang, S. T., Zahn, J. M., Horecka, J., Kunz, P. L., Ford, J. M., & Koong, A. C. (2009). Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. JOURNAL OF TRANSLATIONAL MEDICINE, 7.
-
Escherichia coli O157 : H7 infection in nursing homes: Review of literature and report of recent outbreak
Reiss, G., Kunz, P., Koin, D., & Keeffe, E. B. (2006). Escherichia coli O157 : H7 infection in nursing homes: Review of literature and report of recent outbreak. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 54(4), 680-684.
-
Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus
Vij, R., Triadafilopoulos, G., Owens, D. K., Kunz, P., & Sanders, G. D. (2004). Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus. GASTROINTESTINAL ENDOSCOPY, 60(5), 739-756.
-
Tandem mass spectrometry and newborn screening: Pilot data and review
Filiano, J. J., Bellimer, S. G., & Kunz, P. L. (2002). Tandem mass spectrometry and newborn screening: Pilot data and review. PEDIATRIC NEUROLOGY, 26(3), 201-204.
-
Molecular analysis and prenatal diagnosis of human fumarase deficiency
Coughlin, E. M., Christensen, E., Kunz, P. L., Krishnamoorthy, K. S., Walker, V., & Shih, V. E. (1998). Molecular analysis and prenatal diagnosis of human fumarase deficiency. MOLECULAR GENETICS AND METABOLISM, 63(4), 254-262.
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Patient Comments
Patients comments are gathered from our Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
SHC Patient, Jul 2016
Dr. Kunz was amazing! A great doctor. Knowledgeable, patient, friendly, helpful and put us at ease.
SHC Patient, Jun 2016
Well, I can only that third department continues to give the same care as my experience - thank you. I needed that kind of support.
SHC Patient, Jun 2016
Dr. Kunz provides me with updated options for my care and is very patient and reassuring.
SHC Patient, May 2016
Dr. Kunz is amazing! She is so organized & detail oriented which makes me feel so much better.
SHC Patient, May 2016
Dr. Kunz very informative, kind, caring & professional.
SHC Patient, May 2016
Good experience.
SHC Patient, May 2016
Service Dr. Kunz provided was excellent we discussed some complex treatment plan she made them very clear.
SHC Patient, May 2016
Before appt. was very stressed after. Felt so confident.
SHC Patient, May 2016
Dr. Kunz was a welcome after having to deal with Dr. Cho Nhan. Dr. Kunz discussed my future care with chemotherapy and any issues up to my meeting with her.
SHC Patient, May 2016
I just met PK ? so this was my first time. Hard to rate until I get to know her. But it was a GREAT first encounter.
SHC Patient, Apr 2016
Dr Pam Kunz is the doctor care providers. She spends probably more than allotted time with me. The time to travel is becoming harder to overcome but she is so caring and thorough in providing advice and communicating with my local oncologist - She is tops in our opinion.
SHC Patient, Mar 2016
I am very pleased with Dr. Junz and have confidence in her.
SHC Patient, Mar 2016
I am going to stay in this hospital because they treated me very well I am very happy because you are concerned for the patient and you are very nice.
SHC Patient, Feb 2016
Dr. Kunz is easily the best oncologist I have been to. I have been to Mayo, Froedtert, Oschner & Stafford.
SHC Patient, Feb 2016
Both Dr. Kunz & Theresa were supportive & very positive. I am grateful for their openness & their compassionate care for me.
SHC Patient, Jan 2016
Dr. Kunz & her PA are both top of the line!
SHC Patient, Dec 2015
Dr. Kunz conveys. A sense of complete competence & professionalism while managing at the same time to make one feel as though you are in conversation with a close friend or family member. Best "bedside manner" of ANY physician I've met.
SHC Patient, Dec 2015
Dr. Kunz is the best! I have recommended Dr. Kunz to several other patients in our support group.
SHC Patient, Nov 2015
Dr Kunz is the best of the best.
SHC Patient, Nov 2015
Wonderful concern, understanding care.
SHC Patient, Oct 2015
Overall good.
SHC Patient, Sep 2015
Dr. Kunz is amazing both as a doctor and person.
SHC Patient, Aug 2015
Gorgeous Doctor with a Brilliant mind
SHC Patient, Aug 2015
this was my first visit to Stanford---great experience
SHC Patient, Jul 2015
We love Dr. Kunz!
SHC Patient, Jul 2015
Very good - professional.
SHC Patient, Jun 2015
If I lived in the Bay Area I would have her as my oncologist.
SHC Patient, Jun 2015
Every one in Stanford I have ever dealt with has been very supportive ,funny and very kind and considerate.
SHC Patient, May 2015
I saw the provider for a second opinion on my current diagnosis. She answered questions in ways that made absolute sense. I was advised of a clinical trial that I was not aware of and that I agreed to participate in.
SHC Patient, May 2015
Dr. Kunz is one of the best doctors I have ever seen.
SHC Patient, Apr 2015
DR. Kunz is like a ray of sunshine! I can't endorse her strongly enough. She has always been kind, caring, responsive, patient, and supportive.
SHC Patient, Mar 2015
This is my second clinical trial with Dr. Kunz. I am completely confident in her.
SHC Patient, Feb 2015
I have been very happy with Dr. Kunz in all respects - medical expertise, compassion and genuine concern for my quality of life.
SHC Patient, Feb 2015
We are very thankful to have such a kind & knowledgeable dr. as Dr. Kunz.
SHC Patient, Jan 2015
Pamela Kunz & staff are excellent.
SHC Patient, Jan 2015
Always excellent.
SHC Patient, Jan 2015
Doctor and NP were excellent. Listened well and addressed every concern.
SHC Patient, Jan 2015
It took me too long to finally see Dr. Kunz, but hopefully it was due to her popularity and so many individuals waiting to see her.
SHC Patient, Jan 2015
I don't mind waiting; she takes the time with me if needed too.
SHC Patient, Dec 2014
Great regard & trust in her!
SHC Patient, Nov 2014
For an initial visit she was too brief.
SHC Patient, Oct 2014
We are extremely lucky to have Dr. Kunz.
SHC Patient, Apr 2014
Wait time beyond reasonable!
SHC Patient, Mar 2014
Dr. Kunz and her staff were just wonderful & caring.
SHC Patient, Jan 2014
Dr. Kunz is an excellent professional with fantastic personality.
SHC Patient, Jul 2016
Dr. Kunz was amazing! A great doctor. Knowledgeable, patient, friendly, helpful and put us at ease.
SHC Patient, Jun 2016
Well, I can only that third department continues to give the same care as my experience - thank you. I needed that kind of support.
SHC Patient, Jun 2016
Dr. Kunz provides me with updated options for my care and is very patient and reassuring.
SHC Patient, May 2016
Dr. Kunz is amazing! She is so organized & detail oriented which makes me feel so much better.
SHC Patient, May 2016
Dr. Kunz very informative, kind, caring & professional.
SHC Patient, May 2016
Good experience.
SHC Patient, May 2016
Service Dr. Kunz provided was excellent we discussed some complex treatment plan she made them very clear.
SHC Patient, May 2016
Before appt. was very stressed after. Felt so confident.
SHC Patient, May 2016
Dr. Kunz was a welcome after having to deal with Dr. Cho Nhan. Dr. Kunz discussed my future care with chemotherapy and any issues up to my meeting with her.
SHC Patient, May 2016
I just met PK ? so this was my first time. Hard to rate until I get to know her. But it was a GREAT first encounter.
SHC Patient, Apr 2016
Dr Pam Kunz is the doctor care providers. She spends probably more than allotted time with me. The time to travel is becoming harder to overcome but she is so caring and thorough in providing advice and communicating with my local oncologist - She is tops in our opinion.
SHC Patient, Mar 2016
I am very pleased with Dr. Junz and have confidence in her.
View All 45 Patient Comments »